Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 7/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717911 | 0.89 | TRPV1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4719518 | 0.85 | KDM4E (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4715973 | 0.83 | TRPV1 (0.57) | ABL1TRPV1 | |
| SCHEMBL4719945 | 0.82 | MAPK10 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4719799 | 0.81 | SYK (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4715954 | 0.78 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4716002 | 0.76 | MAPKAPK2 (0.42) | MAPK10SYKABL1MAPKAPK2KIF11 | |
| SCHEMBL4717881 | 0.76 | MAPT (0.53) | MAPK10TRPV1MAPKAPK2 | |
| SCHEMBL4716610 | 0.75 | TRPV1 (0.45) | MAPK10TRPV1CYP3A4 | |
| SCHEMBL4717889 | 0.74 | MAPK10 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442701-B2 | Amino-heterocycles as VR-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1562934-B1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | PSEN1 4099/4885PSEN2 3639/4885APH1B 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.